




Bridging the gap between clinical trials and patients

# Innovative Therapeutics Depends On Patient Inclusion in Clinical Studies



## INCREASING CANCER PATIENTS WORLDWIDE

Source - IARC


19.3 M  
(2020)



28.4 M  
(2040)



**<5%** of cancer patients participate in a clinical study



**>80%** of cancer patients want to participate in a clinical study

**! 80% of studies do not finish on time**

**! Burden of clinical trial system hampers innovation**

# Your clinical trials are always an option

## Addressing bottlenecks in clinical trials



Reducing study-start  
up times




Increasing patient  
enrollment

## OUR APPROACH:


1. 54 sites in reach, 10 sites\* operational for bulk activation with oncologists and patients waiting for trials
2. Single point of contact
3. Fast and efficient study startup (we have already negotiated and collected necessary documents)

\*As of February 2021, anticipated 25 sites by December 2021

## Current



## The iClusion REVOLUTION



# Your clinical trials are always an option



Short overall timelines, starting with swift, easy and transparent service agreement



Single point of contact and single study budget negotiation for study sponsor



Easy and fast study start-up of the whole study site network



Online patient informed consent, inclusion and referral



Promoting your trial in Trial Eye newsflashes and iClusion newsletters



Dedicated people in the field continuously discussing recruitment of trials we support

**YOUR CLINICAL TRIAL SHOULD  
ALWAYS BE AN OPTION**

